STAAR Surgical Company

NasdaqGM:STAA Voorraadrapport

Marktkapitalisatie: US$1.1b

STAAR Surgical Toekomstige groei

Future criteriumcontroles 3/6

STAAR Surgical zal naar verwachting groeien in winst en omzet met respectievelijk 38.1% en 7.7% per jaar. De winst per aandeel zal naar verwachting groeien met 37.4% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.1% zijn.

Belangrijke informatie

38.1%

Groei van de winst

37.38%

Groei van de winst per aandeel

Medical Equipment winstgroei17.0%
Inkomstengroei7.7%
Toekomstig rendement op eigen vermogen6.12%
Dekking van analisten

Good

Laatst bijgewerkt16 Aug 2026

Recente toekomstige groei-updates

Recent updates

Narratiefupdate • Jul 29

STAA: Sector Procedure Risks And China Uncertainty Will Limit Future Upside

The analyst fair value estimate for STAAR Surgical has moved from $23.00 to $20.00, reflecting the new $20 UBS price target and more cautious assumptions, despite generally supportive comments on recent Q1 trends from other firms. Analyst Commentary Recent research on STAAR Surgical reflects a wide range of opinions, with some firms highlighting strong Q1 execution and others leaning more cautious on growth durability and valuation.
Seeking Alpha • Jul 17

STAAR Surgical's Punishment For Opacity Is Just

Summary STAAR Surgical Company shares fell sharply after preliminary Q2 2026 sales met expectations but lacked forward guidance, raising investor concerns. STAA demonstrated robust revenue growth, especially in China and the Americas, with improved margins and cost discipline, but EMEA sales lagged due to geopolitical issues. Despite recent profitability and a strong cash position, uncertainty remains over the sustainability of these improvements and the absence of detailed guidance. I maintain a Sell rating on STAA stock, pending more substantive guidance at the August 12th earnings release to assess if recent gains are sustainable. Read the full article on Seeking Alpha
Narratiefupdate • Jun 30

STAA: Limited China Visibility And Missing Guidance Will Constrain Future Rebound Confidence

The updated analyst price target for STAAR Surgical moves from an implied fair value of $16.00 to $23.00, reflecting adjustments to revenue growth, profit margin, and future P/E assumptions after stronger than expected Q1 results and increased confidence in a China rebound cited by several analysts. Analyst Commentary Recent Street research on STAAR Surgical has centered on stronger than expected Q1 results and growing attention on the China business, but not all commentary is uniformly bullish.
Analyse-artikel • Jun 16

STAAR Surgical (STAA) Stock Could Be 4.4% Undervalued Despite Its Rich P S Multiple

Why STAAR Surgical Stock Is Drawing Attention Now STAAR Surgical (STAA) is back on investors’ radar after a volatile period, with the stock up over the past 3 months but down over the past month and past year. See our latest analysis for STAAR Surgical. Recent trading paints a mixed picture for STAAR Surgical, with the share price at $28.37 after a 90 day share price return of 58.94%, but a 5 year total shareholder return that declined 80.85%. This suggests near term momentum in contrast with...
Narratiefupdate • Jun 16

STAA: China Rebound After Q1 Inflection Will Drive Future Re Rating

STAAR Surgical's analyst price target has been reset from $23.00 to about $39.24, with analysts pointing to stronger than expected Q1 results, signs of a China rebound, and updated long term assumptions on valuation multiples, even as management holds back on formal guidance. Analyst Commentary Recent Street research around STAAR Surgical has turned more constructive, with several bullish analysts lifting price targets and, in some cases, upgrading their ratings following the latest Q1 report.
Narratiefupdate • Jun 02

STAA: China Recovery And Profitability Improvements Will Temper Prior Bearish Reassessment

The analyst price target for STAAR Surgical has shifted from $21.11 to $29.67 as analysts factor in Q1 results that were ahead of expectations, a stronger China contribution, and slightly higher modeled profitability, even as revenue growth assumptions and the projected future P/E are revised. Analyst Commentary Recent research shows a clear shift in sentiment around STAAR Surgical, with several firms lifting price targets following Q1 results that were ahead of expectations.
Narratiefupdate • May 15

STAA: Limited China Visibility And Missing Guidance Will Restrain Future Share Performance

Analysts have raised the fair value estimate for STAAR Surgical stock from $13.00 to $16.00, citing higher price targets supported by stronger Q1 results, improving confidence in a China rebound, and updated models that reflect better profitability assumptions and a lower future P/E multiple. Analyst Commentary Street research on STAAR Surgical has turned more constructive around the recent Q1 update, but the tone is not uniformly positive.
Narratiefupdate • Apr 20

STAA: China Uncertainty And Leadership Transition Will Drive Bearish Reassessment

STAAR Surgical's updated fair value estimate shifts from $26.56 to $21.11 as analysts factor in revised Street targets. These include recent cuts to around $18 to $22 that reflect questions on China exposure and mixed near term visibility, despite some more supportive views emerging.
Narratiefupdate • Apr 06

STAA: China Clarity And Post Alcon Reset Will Drive Future Re Rating

Analysts have trimmed price targets on STAAR Surgical to a range around $18 to $22, with a consensus reset of approximately $23.00, reflecting ongoing questions about China exposure, recent Q4 volatility, and limited near term visibility following the rejected Alcon deal. Analyst Commentary Recent Street commentary around STAAR Surgical centers on uncertainty, but there are pockets of optimism that readers should weigh alongside the more cautious views.
Narratiefupdate • Mar 23

STAA: Ongoing China Uncertainty And Governance Turmoil Will Pressure Shares

Analysts have reduced the consolidated price target for STAAR Surgical to $22 from $28, reflecting lower assumptions for revenue growth and profit margins, a much higher future P/E multiple, and ongoing uncertainty around China and the company’s broader path forward. Analyst Commentary Recent Street research on STAAR Surgical points to a cautious tone, with multiple bearish analysts cutting price targets and reiterating neutral or underweight stances.
Narratiefupdate • Mar 09

STAA: China Clarity And Post Alcon Reset Will Shape Future Upside Potential

Narrative Update on STAAR Surgical Our analyst price target for STAAR Surgical has been revised from $30.75 to $23.00 as analysts factor in recent target cuts, ongoing uncertainty around China and limited near term visibility highlighted in the latest research. Analyst Commentary Recent research on STAAR Surgical has leaned cautious, with multiple firms revising price targets lower and emphasizing uncertainty around the company’s outlook, particularly related to China and the failed Alcon transaction.
Narratiefupdate • Feb 23

STAA: Post Deal Rejection Concerns Will Keep Shares Under Pressure

Analysts have reduced their average price targets on STAAR Surgical by high single digit dollar amounts to around $13.00. This reflects more cautious views on profit margins and valuation multiples after the failed Alcon deal and a series of Neutral and Underweight ratings.
Narratiefupdate • Feb 08

STAA: Post Deal Collapse Uncertainty Will Pressure Shares Until Leadership Path Clears

Narrative Update on STAAR Surgical The analyst price target for STAAR Surgical has been reduced by US$8.75 following a neutral initiation, an Underweight resumption, and cautious commentary from several firms who highlight limited investor appetite until there is greater clarity on the company after the failed Alcon transaction. Analyst Commentary Recent Street research around STAAR Surgical has leaned cautious, with several firms highlighting valuation, execution, and growth risks following the failed Alcon transaction and the subsequent shareholder vote.
Narratiefupdate • Jan 25

STAA: Post Alcon Deal Collapse And CEO Exit Will Cap Near Term Upside

Analysts have trimmed their fair value estimate for STAAR Surgical from US$17.41 to US$13.00, reflecting lower assumed revenue growth and a reduced future P/E multiple, alongside cautious commentary around limited buyer interest and uncertainty following the failed Alcon deal. Analyst Commentary Recent Street research has tilted clearly cautious, with several bearish analysts highlighting valuation pressure, deal uncertainty, and limited near term visibility on the business.
Narratiefupdate • Jan 10

STAA: Failed Alcon Deal And Takeover Optionality Will Reshape Future Appeal

Analysts have lifted their fair value estimate for STAAR Surgical shares from US$28.00 to US$30.75, reflecting updated assumptions on growth, margins and future P/E multiples after recent debate over the failed Alcon deal and the limited near term appeal highlighted in recent research. Analyst Commentary Recent research has centered on the failed Alcon transaction, shareholder pushback on deal terms, and the limited near term appeal cited by several firms.
Narratiefupdate • Dec 26

STAA: Amended Alcon Deal And Activist Push Will Drive Bullish Upside

Analysts have nudged their fair value estimate for STAAR Surgical higher from approximately $25.88 to $26.56. This reflects modestly stronger growth and margin expectations while acknowledging that any amended Alcon deal is unlikely to include a materially higher bid.
Narratiefupdate • Dec 12

STAA: Merger Uncertainty Will Restrain Upside Despite Higher All-Cash Offer

Analysts have modestly raised their price target on STAAR Surgical from $16.00 to approximately $17.41 per share, citing slightly improved assumptions for long term revenue growth, profitability, and future valuation multiples, while they continue to monitor ongoing merger term discussions with Alcon. Analyst Commentary Bearish analysts highlight that the postponed shareholder meeting reinforces uncertainty around the timing and ultimate outcome of the proposed acquisition, which in turn clouds visibility on STAAR Surgical's standalone valuation.
Narratiefupdate • Nov 28

STAA: Amended Merger Terms And Shareholder Opposition Will Guide Share Price Direction

Analysts have maintained their price target for STAAR Surgical at $25.88, citing limited expected upside due to ongoing merger negotiations and continued uncertainty regarding the acquisition terms. Analyst Commentary Market commentary surrounding STAAR Surgical’s ongoing merger negotiations reflects mixed analyst sentiment, with both cautious and optimistic perspectives regarding the company’s prospects and valuation.
Narratiefupdate • Nov 12

STAA: Merger Discussions and Shareholder Opposition Will Shape Path Forward

Analysts have revised STAAR Surgical's price target downward to $16 from previous levels. They cite ongoing shareholder opposition to the proposed merger terms and uncertainty about a potential acquisition price.
Narratiefupdate • Oct 29

Board Opposition And Postponed Vote Will Shape Acquisition Outcome In 2025

Analysts have raised their average price target for STAAR Surgical from $20 to $28 per share. They cite the strategic rationale and valuation of the proposed acquisition by Alcon as key drivers for the upward revision.
Narratiefupdate • Oct 15

Introduction Of EVO+ Will Open Market Opportunities In 2025

Analysts have raised their price target for STAAR Surgical from $24.63 to $25.88. This reflects the impact of an increased acquisition offer and the perceived strategic value from Alcon's proposed purchase.
Narratiefupdate • Aug 20

Introduction Of EVO+ Will Open Market Opportunities In 2025

Analysts have raised their price targets for STAAR Surgical primarily to reflect the proposed $28/share acquisition by Alcon, which sets a new benchmark valuation and limits further upside, resulting in a new consensus fair value of $24.14. Analyst Commentary Bullish analysts raised their price targets to align with the proposed $28/share acquisition price by Alcon.
Narratiefupdate • Aug 06

Introduction Of EVO+ Will Open Market Opportunities In 2025

Driven by a significant improvement in net profit margin despite a higher discount rate, STAAR Surgical's consensus price target has increased from $19.20 to $22.11. What's in the News Alcon Inc.
Analyse-artikel • Jul 04

Getting In Cheap On STAAR Surgical Company (NASDAQ:STAA) Might Be Difficult

There wouldn't be many who think STAAR Surgical Company's ( NASDAQ:STAA ) price-to-sales (or "P/S") ratio of 3.2x is...
Analyse-artikel • Apr 05

Is STAAR Surgical Company (NASDAQ:STAA) Trading At A 37% Discount?

Key Insights The projected fair value for STAAR Surgical is US$25.07 based on 2 Stage Free Cash Flow to Equity Current...
Analyse-artikel • Feb 14

Why Investors Shouldn't Be Surprised By STAAR Surgical Company's (NASDAQ:STAA) 26% Share Price Plunge

Unfortunately for some shareholders, the STAAR Surgical Company ( NASDAQ:STAA ) share price has dived 26% in the last...
Seeking Alpha • Feb 12

STAAR Surgical Q4: Ongoing Challenges In China Masks Healthy Growth Elsewhere

Summary STAAR Surgical's Q4 results were severely impacted by lower demand and high inventory levels in China. Global growth ex-China was 17% in Q4 and is expected to remain strong at 12% for FY25, with US growth of close to 15%. Cash burn is expected to be significant, but the company is financially healthy, having $232 million in cash and no debt on its balance sheet. Following the post-earnings drop, shares are cheaply valued given the long growth runway ahead, which leads me to maintain my Buy rating on STAA stock. Read the full article on Seeking Alpha
Seeking Alpha • Jan 31

STAAR Surgical: Growth Story Remains Intact Despite Some Challenges

Summary Shares have been under pressure lately due to weak demand from China, which is by far the company’s largest market. The market opportunity in the US remains large, and management is investing heavily to tap into it. I have modest expectations for overall growth in FY25 of 9%, with markets excluding China growing significantly faster. The FCF margin in FY25 is expected to be around 8.3% given the ongoing growth investments, while I expect that it can reach close to 20% in the long term. I am assigning a Buy rating on the stock with a target priceof $35, implying an upside of over 45%. Read the full article on Seeking Alpha

Winst- en omzetgroeiprognoses

NasdaqGM:STAA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/202838835315110
12/31/202736128433512
12/31/2026335152912411
7/3/20263404-7-3N/A
4/3/2026290-21-55-50N/A
1/2/2026239-80-40-34N/A
9/26/2025231-96-40-30N/A
6/27/2025224-95-44-29N/A
3/28/2025279-71-31-12N/A
12/27/2024314-20-816N/A
9/27/2024341222647N/A
6/28/2024333171437N/A
3/29/2024326152141N/A
12/29/202332221-415N/A
9/29/202331020-34-14N/A
6/30/202330626-116N/A
3/31/2023295331735N/A
12/30/2022284401836N/A
9/30/2022279382241N/A
7/1/2022262342439N/A
4/1/2022243291933N/A
12/31/2021230283044N/A
10/1/2021217234455N/A
7/2/2021206213242N/A
4/2/2021179112836N/A
1/1/202116361321N/A
10/2/20201569211N/A
7/3/20201487413N/A
4/3/202015313N/A17N/A
1/3/202015014N/A26N/A
9/27/20191429N/A18N/A
6/28/20191358N/A15N/A
3/29/20191296N/A11N/A
12/28/20181245N/A13N/A
9/28/20181184N/A12N/A
6/29/20181093N/A7N/A
3/30/2018971N/A6N/A
12/29/201791-2N/A3N/A
9/29/201788-2N/A2N/A
6/30/201784-5N/A0N/A
3/31/201784-6N/A3N/A
12/30/201682-12N/A1N/A
9/30/201681-13N/A-1N/A
7/1/201680-13N/A-1N/A
4/1/201678-12N/A-3N/A
1/1/201677-7N/A-2N/A
10/2/201573-8N/A-4N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei STAA ( 38.1% per jaar) ligt boven de spaarquote ( 3.7% ).

Winst versus markt: De winst van STAA ( 38.1% per jaar) zal naar verwachting sneller groeien dan de US markt ( 17.2% per jaar).

Hoge groeiwinsten: De winst van STAA zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van STAA ( 7.7% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 13.4% per jaar).

Hoge groei-inkomsten: De omzet van STAA ( 7.7% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen STAA zal naar verwachting over 3 jaar laag zijn ( 6.1 %).

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2026/09/14 09:23
Aandelenkoers aan het einde van de dag2026/09/11 00:00
Inkomsten2026/07/03
Jaarlijkse inkomsten2026/01/02

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

STAAR Surgical Company wordt gevolgd door 20 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Michael GormanBTIG
William PlovanicCanaccord Genuity
John YoungCanaccord Genuity